Oct. 29, 2025 — FastWave Medical presented new first-in-human (FIH) and pre-clinical data for its Sola coronary laser intravascular lithotripsy (L-IVL) system at TCT 2025 (Transcatheter Cardiovascular Therapeutics) in San Francisco.

Oct. 27, 2025 — At the annual Transcatheter Cardiovascular Therapeutics (TCT 2025) meeting in San Francisco, Royal Philips introduced its latest innovation that integrates pre-operative CT data directly into the cath lab workflow. This new capability, available through the integration of Philips’ Advanced Visualization Workspace (AVW) with the Azurion image-guided therapy system, marks a first step towards CT-guided percutaneous coronary intervention (PCI), a minimally invasive procedure to open narrowed coronary arteries and restore blood flow to the heart.

Oct. 27, 2025 — Results from the PREVUE-VALVE study suggest that there are currently at least 4.7 million people aged 65-85 living with moderate or greater valvular heart disease (VHD) in the United States, and at least 10.6 million with clinically significant VHD, most of whom are unaware of their condition. The prevalence of VHD increases sharply with advanced age — a finding that suggests a need for screening and treatment programs to ensure broad access to appropriate care. 

Oct. 28, 2025 — People who underwent a minimally invasive procedure to have their heart’s aortic valve replaced had similar health outcomes years after treatment as people who had surgery, Cedars-Sinai investigators and colleagues report.

Oct., 2025 — Elucid, an AI medical technology company focused on providing physicians with a more precise view of atherosclerosis, has introduced its PlaqueIQ image analysis software for the quantification and classification of plaque morphology in the carotid arteries. The first and only CT-based plaque analysis software indicated for the carotid vasculature, PlaqueIQ may help physicians diagnose carotid plaques at risk for rupture and develop patient-specific treatment pathways to prevent and monitor against ischemic stroke.

Oct. 22, 2025 – Ventric Health, a medtech innovator enabling early detection of heart failure (HF) in a primary care setting, has commenced enrollment in a large study comparing the company’s non-invasive Vivio System with the leading invasive implant to determine their respective abilities to effectively measure HF status over time and enable physicians to reduce patient hospitalizations and death.

Oct. 25, 2025 — Medtronic plc has announced the launch of the Stedi Extra Support guidewire, designed to enhance performance of the Evolut transcatheter aortic valve replacement (TAVR) platform — and compatible with all commercially available TAVR systems — for patients with severe aortic stenosis.The announcement took place at the 2025 Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco, Calif.

Oct. 27, 2025 — Elixir Medical, a developer of technologies to treat cardiovascular disease, has announced new clinical results for its DynamX bioadaptor, a coronary implant designed to restore a blood vessel’s natural movement and function, also known as hemodynamic modulation, demonstrating a 48% risk reduction in device-related cardiac events compared to current-generation drug-eluting stent.

Oct. 23, 2025— Emboline, Inc., a provider of full-body embolic protection devices for transcatheter procedures, thas completed patient enrollment in its Protect the Head to Head (ProtectH2H) Clinical Trial, a pivotal Investigational Device Exemption (IDE) trial (NCT05684146) evaluating the safety and effectiveness of the Emboliner Embolic Protection Catheter for patients undergoing Transcatheter Aortic Valve Replacement/Implant (TAVR/TAVI). Enrollment began in May 2023.

Oct. 26, 2025 – Jupiter Endovascular, Inc., a medical technology company developing a new class of endovascular interventions using its Transforming Fixation (TFX) technology, announced positive results from the SPIRARE I first-in-human (FIH) study. Data was presented at the Transcatheter Cardiovascular Therapeutics (TCT 2025) conference by Professor Irene Lang, MD, Principal Investigator and Professor of Vascular Biology at the Medical University of Vienna in Austria.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now